---
figid: PMC12205216__MCO2-6-e70278-g001
figtitle: Natural products targeting TGF‐B pathway in treatment of prostate cancer
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC12205216
filename: MCO2-6-e70278-g001.jpg
figlink: /pmc/articles/PMC12205216/figure/F5/
number: F5
caption: Natural products targeting TGF‐β pathway in treatment of prostate cancer.
  This figure shows the impact of various natural products on the TGF‐β signaling
  pathway in prostate cancer (PC). Panel A includes cell lines DU145, PC‐3, and LNCaP,
  and highlights compounds thymoquinone (ThQ), hesperetin (HesP), genistein (GenS),
  apigenin (ApG), and γ‐tocotrienol (GT3) that inhibit TGF‐β signaling. These compounds
  affect EMT suppressor genes like E‐cadherin and EMT trigger genes like slug, vimentin,
  and N‐cadherin, angiogenesis genes like VEGF, and key signaling molecules like Src,
  FAK, Akt, NF‐κB, MEK3/6, and TAK‐1. Panel B continues with additional cell lines
  including a rat model of metastatic hereditary castration‐resistant prostate cancer
  (hCRPC) and shows compounds curcumin (Crc), red clove isoflavones (RC), quercetin
  (QuerC), digitoxin (DigiT), osthole (OsT), and silibinin (SilB). These compounds
  inhibit tumor suppressor genes like PTEN, apoptotic trigger genes like caspase‐3,
  cell proliferative genes like MYC and cyclin D1, extracellular matrix degrader genes
  like MMP‐9, and EMT trigger genes. Akt, protein kinase B; ApG, apigenin; Crc, curcumin;
  DigiT, digitoxin; DU145, brain metastasis of grade II epithelial prostate adenocarcinoma;
  E‐cadherin, epithelial cadherin; EMT, epithelial–mesenchymal transition; FAK, focal
  adhesion kinase; GT3, γ‐tocotrienol; HesP, hesperetin; hCRPC, metastatic hereditary
  castration‐resistant prostate cancer; LNCaP, left supraclavicular lymph node of
  human prostate carcinoma; MEK3/6, mitogen‐activated protein kinase 3/6; NF‐κB, nuclear
  factor kappa‐light‐chain‐enhancer of activated B cells; N‐cadherin, neural cadherin;
  OsT, osthole; PC, prostate cancer; PC‐3, bone metastasis of grade IV prostatic adenocarcinoma;
  PTEN, phosphatase and tensin homolog; QuerC, quercetin; RC, red clove isoflavones;
  SilB, silibinin; Slug, zinc finger protein SNAI1; Smad, mothers against decapentaplegic
  homolog; Src, proto‐oncogene tyrosine‐protein kinase src; TAK‐1, transforming growth
  factor beta‐activated kinase 1; TGF‐β, transforming growth factor‐beta; ThQ, thymoquinone;
  VEGF, vascular endothelial growth factor; vimentin, intermediate filament protein
papertitle: 'Transforming Growth Factor‐β Pathway: Biological Functions and Therapeutic
  Targets'
reftext: Reham Hassan Mekky, et al. MedComm (2020). 2025 Jul;6(7).
year: '2025'
doi: 10.1002/mco2.70278
journal_title: MedComm
journal_nlm_ta: MedComm (2020)
publisher_name: Wiley
keywords: angiogenesis | apoptosis | cancer progression | natural compounds | TGF‐β
  pathway | therapeutic modulation
automl_pathway: 0.8907701
figid_alias: PMC12205216__F5
figtype: Figure
redirect_from: /figures/PMC12205216__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12205216__MCO2-6-e70278-g001.html
  '@type': Dataset
  description: Natural products targeting TGF‐β pathway in treatment of prostate cancer.
    This figure shows the impact of various natural products on the TGF‐β signaling
    pathway in prostate cancer (PC). Panel A includes cell lines DU145, PC‐3, and
    LNCaP, and highlights compounds thymoquinone (ThQ), hesperetin (HesP), genistein
    (GenS), apigenin (ApG), and γ‐tocotrienol (GT3) that inhibit TGF‐β signaling.
    These compounds affect EMT suppressor genes like E‐cadherin and EMT trigger genes
    like slug, vimentin, and N‐cadherin, angiogenesis genes like VEGF, and key signaling
    molecules like Src, FAK, Akt, NF‐κB, MEK3/6, and TAK‐1. Panel B continues with
    additional cell lines including a rat model of metastatic hereditary castration‐resistant
    prostate cancer (hCRPC) and shows compounds curcumin (Crc), red clove isoflavones
    (RC), quercetin (QuerC), digitoxin (DigiT), osthole (OsT), and silibinin (SilB).
    These compounds inhibit tumor suppressor genes like PTEN, apoptotic trigger genes
    like caspase‐3, cell proliferative genes like MYC and cyclin D1, extracellular
    matrix degrader genes like MMP‐9, and EMT trigger genes. Akt, protein kinase B;
    ApG, apigenin; Crc, curcumin; DigiT, digitoxin; DU145, brain metastasis of grade
    II epithelial prostate adenocarcinoma; E‐cadherin, epithelial cadherin; EMT, epithelial–mesenchymal
    transition; FAK, focal adhesion kinase; GT3, γ‐tocotrienol; HesP, hesperetin;
    hCRPC, metastatic hereditary castration‐resistant prostate cancer; LNCaP, left
    supraclavicular lymph node of human prostate carcinoma; MEK3/6, mitogen‐activated
    protein kinase 3/6; NF‐κB, nuclear factor kappa‐light‐chain‐enhancer of activated
    B cells; N‐cadherin, neural cadherin; OsT, osthole; PC, prostate cancer; PC‐3,
    bone metastasis of grade IV prostatic adenocarcinoma; PTEN, phosphatase and tensin
    homolog; QuerC, quercetin; RC, red clove isoflavones; SilB, silibinin; Slug, zinc
    finger protein SNAI1; Smad, mothers against decapentaplegic homolog; Src, proto‐oncogene
    tyrosine‐protein kinase src; TAK‐1, transforming growth factor beta‐activated
    kinase 1; TGF‐β, transforming growth factor‐beta; ThQ, thymoquinone; VEGF, vascular
    endothelial growth factor; vimentin, intermediate filament protein
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PC
  - BCR
  - IGKV3D-20
  - CRP
  - CSRP1
  - PPIAP10
  - IK
  - DYRK3
  - Cancer
  - Prostate Cancer
---
